Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer

BACKGROUND: Immunotherapy, monotherapy, and immunotherapy plus platinum-based chemotherapy are the standard treatments for advanced non-small cell lung cancer (NSCLC) patients with negative driver genes. However, the impact of similar continuing immunotherapy beyond progression (IBP) of first-line i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Manyi, Hao, Yue, Zeng, Xiaohong, Si, Jinfei, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183556/
https://www.ncbi.nlm.nih.gov/pubmed/37197488
http://dx.doi.org/10.21037/jtd-22-1611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183556/
https://www.ncbi.nlm.nih.gov/pubmed/37197488
http://dx.doi.org/10.21037/jtd-22-1611

Ejemplares similares